|
|
|
|
|
|
|
Cell 2026 | 12-13 November, London, UK
|
Advanced therapy development moves fast, and the companies shaping it are the ones connecting science, scale and strategy in the same room. Cell 2026 is where that happens. Partner with us to reach 800+ senior pharma, biotech and R&D decision-makers through guaranteed 1:1 meetings, speaking slots, roundtables and tailored digital campaigns. Get in touch and we'll design a package around your objectives.
|
|
|
|
|
|
|
|
|
|
|
|
Consistency You Can Trust in Animal‑Free Raw Materials
|
|
Infographic | Nu-Tek Biosciences
|
Animal‑free raw materials ensure reliable bioprocessing through stable molecular weight profiles, consistent mineral levels, and controlled manufacturing for dependable lot‑to‑lot performance.
|
|
|
|
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma
|
There’s something sadly predictable about negative media reaction to a woman whose professional accomplishments ought to command attention before anything else, writes Chief Editor Louis Garguilo. "But what interests others heading into the Heidi Overton nomination process for FDA Commissioner is whether she can guide the FDA to help us get medicines developed, manufactured, and approved. So what kind of FDA does the outsourcing supply chain need?"
|
|
|
|
|
|
The U.S. Supply-Chain Uncovered: A Superior Search For Domestic Suppliers
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma
|
The search for supply chain partners goes on. Intensely. But productively? Are we missing anything? We are about to learn the answer to that is yes. Alan Davis, President & CEO, i5 Services says puzzling is how little these searches vary – and he's concerned that invariance has negative national supply-chain implications. He has a mission and a search platform to change that.
|
|
|
|
Is mRNA Manufacturing Overbuilt?
|
|
By Nigel Horscroft, independent biotech consultant
|
mRNA pipelines continue to advance, but has provider growth outpaced the pipeline? Let's take a closer look.
|
|
|
|
INDUSTRY INSIGHTS CONTINUED
|
|
|
|
|
|
|
|
Lentiviral Solutions: Fast Lane To The Clinic
|
|
Infographic | Aldevron
|
Vector redesign and regulatory hurdles can add years to development timelines. A single-partner approach helps streamline the process, secures timelines, and ensures smooth tech transfer.
|
|
|
|
|
|
The Advantages Of Off-The-Shelf GMP iPSCs With A DMF
|
|
Webinar | Applied StemCell
|
Learn how off-the-shelf, GMP-grade iPSC lines with a Drug Master File (DMF) can accelerate cell therapy development, streamline regulatory approval, and reduce time and cost to clinic.
|
|
|
|
|
|
|
|
|
|
Accelerated Development Backed By Experience
|
|
Article | By Dr. Megan Mason and Dr. James Berry, Lonza
|
A biologics development strategy can achieve IND readiness in as little as six months by combining workflows, early risk mitigation, advanced technologies, robust analytics, and regulatory planning.
|
|
|
|
|
|
Nucleic Acid-LNP Ultrafiltration And Diafiltration
|
|
White Paper | Recipharm Advanced Bio
|
Downstream filtration can make or break LNPs at scale. See how membrane format, loading, and shear affect recovery and stability — and how alternative TFF lowers scale‑up risk.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE
|
|
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.
|
|
|
| Connect With Outsourced Pharma: |
|
|
|
|
